Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex

Molecular Medicine Reports

Volumn 8, Issue 3, 2013, Pages 887-890

  Yang, Chun ^a   Shen, Jiang ^a   Hong, Tao ^a   Hu, Ting Ting ^a   Li, Zhang Jun ^a   Zhang, Hai Tao ^a   Zhang, Yong Jun ^a   Zhou, Zhi Qiang ^b   Yang, Jian Jun ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Depressive like behavior; Inflammatory cytokines; Ketamine; Lipopolysaccharide; Prefrontal cortex

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETAMINE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; CYTOKINES; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; KETAMINE; LIPOPOLYSACCHARIDES; MALE; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, WISTAR;

EID: 84881122352     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1600     Document Type: Article

References (23)

1. Aan Het Rot M, Zarate CA Jr, Charney DS and Mathew SJ: Ketamine for depression: where do we go from here? Biol Psychiatry 72: 537-547, 2012.
2. Mathew SJ, Shah A, Lapidus K, et al: Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26: 189-204, 2012.
3. Machado-Vieira R, Salvadore G, Diazgranados N and Zarate CA Jr: Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123: 143-150, 2009.
4. Krystal JH: Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 137: 215-216, 2007.
5. Li N, Lee B, Liu RJ, et al: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964, 2010.
6. Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F and Marazziti D: Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18: 245-255, 2011.
7. Hayley S, Poulter MO, Merali Z and Anisman H: The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 135: 659-678, 2005.
8. Raedler TJ: Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 24: 519-525, 2011.
9. De Berardis D, Conti CM, Serroni N, et al: The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 23: 417-422, 2010.
10. Song C and Wang H: Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 760-768 2011.
11. Hosseini M, Zakeri S, Khoshdast S, et al: The effects of Nigella sativa hydro-alcoholic extract and thymoquinone on lipopolysaccharide-induced depression like behavior in rats. J Pharm Bioallied Sci 4: 219-225, 2012.
12. Park SE, Lawson M, Dantzer R, Kelley KW and McCusker RH: Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. J Neuroinflammation 8: 179, 2011.
13. Loix S, De Kock M and Henin P: The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg 62: 47-58, 2011.
14. Sun J, Zhou ZQ, Lv R, Li WY and Xu JG. Ketamine inhibits LPS-induced calcium elevation and NF-kappa B activation in monocytes. Inflamm Res 53: 304-308, 2004.
15. Yang JJ, Zhou ZQ and Yang C: Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines? Psychol Med 41: 1787, 2011.
16. Porsolt RD, Le Pichon M and Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732, 1977.
17. Herzum I and Renz H: Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 15: 581-587, 2008.
18. Biswas SK and Lopez-Collazo E: Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30: 475-487, 2009.
19. Dunn AJ, Swiergiel AH and de Beaurepaire R: Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29: 891-909, 2005.
20. Kang A, Hao H, Zheng X, et al: Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflammation 8: 100, 2011.
21. Taniguchi T and Yamamoto K: Anti-inflammatory effects of intravenous anesthetics on endotoxemia. Mini Rev Med Chem 5: 241-245, 2005.
22. Yang C, Li WY, Yu HY, et al: Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex. J Biomed Biotechnol 2012: 175619, 2012.
23. Yang C, Hong T, Shen J, et al: Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus. Exp Ther Med 5: 1093-1096, 2013.